Publication Name	World Journal of Hepatology
Manuscript ID	6852
Country	United States

Received	2013-10-29 15:31
Peer-Review Started	2013-10-30 16:40
First Decision by Editorial Office Director
Return for Revision	2013-12-30 16:01
Revised	2014-01-08 00:44
Publication Fee Transferred
Second Decision by Editor	2014-03-12 18:35
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-03-12 18:42
Articles in Press
Edit the Manuscript by Language Editor	2014-03-29 02:12
Typeset the Manuscript	2014-05-08 20:33
Publish the Manuscript Online	2014-05-20 15:05

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Zeynel Abidin Ozturk and Abdurrahman Kadayifci
Funding Agency and Grant Number
Corresponding Author	Dr. Abdurrahman Kadayifci, MD, 3-H GI Associates, Zero Emerson Place, Blossom St. Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, United States. akadayifci@mgh.harvard.edu
Key Words	Insulin sensitizers; Metformin; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Thiazolidinediones
Core Tip	Non-alcoholic fatty liver disease (NAFLD) is increasing significantly due to the obesity epidemic. Insulin resistance, mainly caused by obesity, plays a primary role in NAFLD pathogenesis. Medications that improve insulin sensitivity are theorized to be useful in the treatment of NAFLD. Therefore, recent studies have explored the role of insulin sensitizers to improve biochemical and histological features of NAFLD.
Publish Date	2014-05-20 15:05
Citation	Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol 2014; 6(4): 199-206
URL	http://www.wjgnet.com/1948-5182/full/v6/i4/199.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i4.199

Full Article (PDF)	WJH-6-199.pdf
Full Article (Word)	WJH-6-199.doc
Manuscript File	6852-Review.doc
Answering Reviewers	6852-Answering reviewers.pdf
Copyright License Agreement	6852-Copyright assignment.pdf
Peer-review Report	6852-Peer review(s).pdf
Scientific Editor Work List	6852-Scientific editor work list.doc